REG - Angle PLC - Analysis of CTC-DNA and ctDNA using Illumina assay

AngleAnnouncement

29/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250129:nRSc0239Va&default-theme=true

RNS Number : 0239V  Angle PLC  29 January 2025

 For immediate release  29 January 2025

 

ANGLE plc ("the Company")

 

NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and
sequencing platform

 

Findings in lung cancer show that CTCs can provide additional biomarkers not
found in ctDNA from single blood sample

 

ANGLE invited to present data at EACR-Illumina webinar on 6 February 2025

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is delighted to announce new, successful
results for the Company's dual circulating tumour DNA (ctDNA) and CTC-DNA
workflow using, for the first time, an end-to-end Illumina solution for
analysis.

 

Over the last six months, ANGLE has overcome technical issues to successfully
use Illumina assays, coupled with their next generation sequencing (NGS)
platform, to provide a complete solution for the dual analysis of CTCs and
ctDNA. In the study, ctDNA was first isolated from the plasma and CTCs were
isolated and harvested using the Parsortix(®) system from a single blood tube
taken from 27 lung cancer patients. CTCs and ctDNA were then analysed using
Illumina's customised 79 gene lung cancer panel with NGS completed on the
Illumina NextSeq 2000 platform.

 

In the patients that had not received any treatment (n=8), 100% had cancer
mutations identified that were identified only in the CTC-DNA and not in the
ctDNA.  In patients that had received treatment or were currently on
treatment (n=19), 90% had cancer mutations identified only in the CTC-DNA and
not in the ctDNA. There were also mutations identified in ctDNA alone that
were not found in CTCs. This evidence confirms the importance of including
CTC-DNA analysis alongside ctDNA so that clinically relevant cancer mutations
are not missed. Analysing both analytes found twice as many mutations, which
could be used as potential biomarkers to guide treatment.

 

As a result of these positive findings and their importance to both companies,
Illumina has assigned their entire European Association for Cancer Research
(EACR) webinar to ANGLE's findings. The webinar, entitled 'Complementary
insights: Exploring the dual analysis of circulating tumour cells and
circulating DNA', will present ANGLE's results on 6 February 2025 at 16:00
GMT.

 

ANGLE is keen to align the Parsortix system with Illumina's NGS instruments
and gene panels in the future as the combination enables Illumina's customers
to introduce Parsortix-based CTC analysis for DNA dual analysis NGS
sequencing, enabling analysis of large gene panels and cancer specific
mutations. Illumina is the world's largest provider of NGS systems and assays
and has built an installed base of more than 23,000 sequencing systems across
more than 9,500 customers in 155 countries.

 

The webinar is the first joint marketing initiative for ANGLE and Illumina.
Because it harvests intact cancer cells (rather than DNA fragments of dead
cells), ANGLE's Parsortix system offers the potential to undertake multiomics
by enabling RNA and protein sequencing on Illumina platforms which is not
possible with ctDNA. Furthermore, as a liquid biopsy analyte it provides for
minimally invasive, repeatable sampling not possible with tissue biopsy.

 

To sign up for the live webinar or to access the recording please use the
link:

www.eacr.org/meeting/illumina-webinar-feb25
(http://www.eacr.org/meeting/illumina-webinar-feb25)

 

ANGLE Chief Scientific Officer, Karen Miller, commented:

"We are excited at the prospect of combining ANGLE's Parsortix system with
Illumina's NGS assays and optimising a workflow that will enable Illumina
customers to offer CTC analysis in the future. Furthermore, as our research
has previously shown, simultaneous analysis of CTCs and ctDNA from the same
tube of blood significantly expands the potential for liquid biopsy research
and clinical drug discovery and development. Information provided by these
analytes is complementary and has the potential to provide a more
comprehensive profile of a patient's cancer when compared to information
derived from either CTCs or ctDNA alone."

 

ANGLE Chief Executive, Andrew Newland, added:

"We see a substantial opportunity for both ANGLE and Illumina to work closely
together and are grateful to Illumina for the opportunity to present our DNA
dual analysis data at their webinar hosted by the highly rated EACR."

 

Background Information

ANGLE has already reported (RNS announcement dated 4 January 2024) on the
successful development of a workflow for the dual analysis of CTC-DNA and
ctDNA using the Illumina platform with a third-party assay kit (now under
option for exclusive licence by ANGLE). In the forty-seven-patient study
across four cancer types (breast, lung, ovarian and prostate), a significant
number of patients had clinically relevant mutations found in their CTCs that
were not present in ctDNA from the same blood draw. This data further
validates these findings.

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014). Upon the publication of this announcement via a
regulatory information service, this information is considered to be in the
public domain.

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on clinical services and diagnostic
products. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made assay development
and clinical trial testing for pharma. Products include the Parsortix system,
associated consumables and assays.

 

Over 100 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

Any reference to regulatory authorisations such as FDA clearance, CE marking
or UK MHRA registration shall be read in conjunction with the full intended
use of the product:

 

The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer.  The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood.  The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays.  The end
user is responsible for the validation of any downstream assay.  The
standalone device, as indicated, does not identify, enumerate or characterize
CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs,
including monitoring indications or as an aid in any disease management and/or
treatment decisions.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESEAXFPASKSEFA